Radiology content commonly referenced by physicians includes imaging guidelines, safety recommendations, clinical trials, radiopharmaceutical guidance, and standardized reporting systems. The following 10 resources address imaging selection, safety, screening, diagnosis, treatment, and reporting across radiology practice.

1. American College of Radiology (ACR) Appropriateness Criteria — The ACR Appropriateness Criteria provide evidence-based guidance for physicians and other health care providers when selecting imaging or treatment for specific clinical situations.

2. ACR Manual on Contrast Media — The ACR Manual on Contrast Media provides guidance for radiologists on recognizing and managing risks associated with contrast media. It addresses patient risk and potential benefit, alternative imaging approaches, clinical indications for contrast administration, and preparation for adverse events.

3. ACR Manual on Magnetic Resonance (MR) Safety — The ACR Manual on MR Safety provides guidance for practitioners on safety practices in clinical and research MR environments. The recommendations are intended to support appropriate radiologic care, and the web-based manual may be revised and updated over time.

4. ACR Breast Imaging Reporting and Data System (BI-RADS) v2025 — The ACR BI-RADS v2025 is designed to support breast imaging reporting and performance evaluation. It includes sections on mammography, ultrasound, MRI, contrast-enhanced mammography, and audit and outcomes monitoring.

5. GÖTEBORG-2 Prostate Cancer Screening Trial — The population-based GÖTEBORG-2 trial evaluated prostate cancer screening using prostate-specific antigen testing, MRI, and different biopsy strategies. At a median follow-up of 3.9 years, omitting biopsy in patients with negative MRI results reduced diagnoses of clinically insignificant prostate cancer by more than half compared with a systematic biopsy strategy.

6. SCEMAM Trial — The prospective SCEMAM trial evaluated contrast-enhanced mammography added to digital breast tomosynthesis in women eligible for screening MRI. Among 601 women who completed contrast-enhanced mammography, cancers in 6 women were identified with just contrast-enhanced mammography. For reader 1, adding contrast-enhanced mammography to digital breast tomosynthesis increased the false-positive rate.

7. Floretyrosine F 18 (Pixclara) — The US Food and Drug Administration (FDA) approved floretyrosine F 18 (Pixclara) for use with positron emission tomography (PET) to distinguish recurrent or progressive glioma from treatment-related changes when used with other diagnostic evaluations.

8. Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) — The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen receptor pathway inhibitor therapy among adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation–naive or –sensitive prostate cancer. Patient selection is based on tumor PSMA expression using an approved PSMA PET product.

9. Lung Computed Tomography Imaging Reporting and Data System (Lung-RADS) v2022 — The ACR Lung-RADS v2022 provides evidence-based classification and management guidance for findings identified during lung cancer screening. When supporting data are unavailable, the guidance incorporates expert consensus.

10. Liver Imaging Reporting and Data System (LI-RADS) — The ACR LI-RADS standardizes reporting and data collection for computed tomography and MRI of hepatocellular carcinoma. Among patients with risk factors for hepatocellular carcinoma, the system uses consistent terminology and is intended to reduce variability and errors in imaging interpretation, support communication with referring clinicians, and contribute to quality assurance and research.

Sources: ACR, The New England Journal of Medicine, Radiology, FDA